Compare Amgen, Inc. (AMGN) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Funko Inc — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Funko Inc trades at $5.67 (market cap $311.58M). The key difference: Amgen, Inc. is far larger — about 629.4× Funko Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| AMGN | FNKO | |
|---|---|---|
Market Cap | $196.12B | $311.58M |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $5.88 |
52-Week Low | $271.18 | $2.46 |
Enterprise Value | $241.41B | $556.62M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FNKO trades at $5.58, up 3.91% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with revenue declining to $908M in 2025 and a net loss of $67M, though recent quarters beat EPS estimates. Analyst consensus is divided with 42.9% buy ratings, while positive news includes new product launches and Q1 2026 revenue growth to $200.9M. Cash flow improved to a net positive $7.5M in 2025 from negative trends in prior years.
Outlook remains cautious due to persistent losses and high debt, but recent execution improvements and product innovation offer potential upside. Key risks include margin pressure and competitive threats in the collectibles market. Investors should weigh the bullish analyst sentiment against fundamental challenges before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
